Company / Shareholders' Equity
Atea Pharmaceuticals, Inc. Shareholders' Equity History
FY2020-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$640.6M
FY2022
5-year range
-$49.6M / $640.6M
FY2020-FY2022
Trend
+1392.2%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity changed +1392% YoY in FY2022, a notable deviation from the 2-year average annual change of +678%.
Based on SEC 10-K filings.
$641M in FY2022.
Improved from -$36M to $641M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, shareholders' equity increased 1392.2% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 10.30 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $640.6M | +1392.2% |
| FY2021 | -$49.6M | -37.1% |
| FY2020 | -$36.2M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026